Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

Rallybio is headed into a mid-stage trial with enough cash through 2026, but the cyclical market has made the journey ...

Under the terms of the license agreement, Monopar will pay Alexion an upfront cash payment and equity ... and other organs.

A total of 57 abstracts will feature 13 approved and potential new medicines from across AstraZeneca’s portfolio and pipeline in haematology, including from Alexion, its rare disease group, with data ...

WILMETTE, Ill., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with ...

His company, Wilmette-based Monopar Therapeutics, announced yesterday it has entered a licensing deal with Alexion and its parent, AstraZeneca, to further develop ALXN-1840, or bis-choline ...

Monopar entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 for Wilson disease. ALXN-1840 has advanced through a Phase 3 clinical trial ...

Monopar Therapeutics (NASDAQ:MNPR) rose around 20% ahead of trading on Thursday after it announced an agreement with Alexion, ...

Monopar Therapeutics' market value nearly tripled Thursday after the biotechnology company agreed to license a treatment for patients with a rare genetic condition from AstraZeneca unit Alexion.

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials ...

today announced that it has entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate), a drug candidate for ...

Monopar Therapeutics, Inc. (NASDAQ:MNPR) shares are trading lower Friday after gaining on Thursday. The stock was volatile ...